<DOC>
	<DOCNO>NCT02035787</DOCNO>
	<brief_summary>Purpose : This open label , single-arm , single-center study addition metformin standard levonorgestrel-releasing intrauterine device ( LR-IUD ) treatment 30 evaluable non-surgical patient either complex atypical hyperplasia ( CAH ; n=15 ) grade 1 endometrial adenocarcinoma ( EC ; n=15 ) . Participants : Women , age 18 year , biopsy-proven CAH/EC candidate surgical management , therefore plan start standard care treatment LR-IUD Procedures ( method ) : subject give oral metformin therapy 12 month , disease progression occur ( whichever occurs first ) , addition LR-IUD treatment . Serial endometrial biopsy perform , per standard care , assess disease status .</brief_summary>
	<brief_title>Metformin With Levonorgestrel-Releasing Intrauterine Device Treatment Complex Atypical Hyperplasia ( CAH ) Endometrial Cancer ( EC ) Non-surgical Patients</brief_title>
	<detailed_description>STUDY OBJECTIVES Primary Objective -To compare rate CR 6 month non-surgical grade 1 EC CAH patient receive metformin + LR-IUD 50 % Secondary Objectives - estimate rate CR 6 month separately grade 1 EC CAH patient receive metformin + LR-IUD - estimate rate CR 12 month non-surgical grade 1 EC CAH patient receive metformin + LR-IUD - document patient adherence long-term ( ≥3 month ) metformin administration - To describe safety metformin + LR-IUD treatment Exploratory Objectives - To explore change cellular proliferation measure marker , Ki-67 , baseline 6 month - To explore association level expression metformin transporter proteins key target metformin/mTOR signal pathway CR status 6 month - To perform comprehensive unbiased profiling metabolite analyze metabolic `` fingerprint '' biofluids ( i.e . serum urine ) `` footprint '' tumor tissue pre- post- 6 month metformin treatment - To explore association metabolic factor metformin concentration level tumor tissue/blood/urine CR 6 month This open label , single-arm , single-center study addition metformin standard levonorgestrel-releasing intrauterine device ( LR-IUD ) treatment 30 evaluable non-surgical patient either complex atypical hyperplasia ( CAH ; n=15 ) grade 1 endometrial adenocarcinoma ( EC ; n=15 ) . Women , age 18 year , biopsy-proven CAH/EC candidate surgical management , therefore plan start standard care treatment LR-IUD , give oral metformin therapy 12 month , disease progression occur ( whichever occurs first ) , addition LR-IUD treatment . Serial endometrial biopsy perform , per standard care , assess disease status . We hypothesize addition metformin standard LR-IUD treatment CAH grade 1 EC result complete response ( CR ) rate 6 month significantly high 50 % population non-surgical candidate . In addition , plan estimate CR rate 6 month CAH EC separately , group whole 12 month . We also document rate patient adherence long-term metformin therapy .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Endometrial Neoplasms</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<mesh_term>Levonorgestrel</mesh_term>
	<criteria>Subjects must meet inclusion criterion participate study : Histologically confirm CAH grade 1 EC Females age ≥ 18 year ECOG Performance Status 0 4 Nonsurgical candidate due : Desire fertility preserve treatment Unacceptable surgical risk define : oAmerican Society Anesthesiologists Physical Status ( ASA ) ≥ 4 and/or Perioperative Cardiac Risk &gt; 5 % ( 45 ) and/or Perioperative Respiratory Failure Risk &gt; 5 % ( 46 ) AND oIndependent medicine cardiology preop consultation conclude 'high ' surgical risk . Planned treatment LRIUD CAH grade 1 EC primary physician Women childbearing potential ( WOCBP ) must negative pregnancy test within 7 day D1 treatment Understand study design , risk , benefit sign informed consent Exclusion Criteria Any patient meeting exclusion criterion baseline exclude study participation . Evidence renal dysfunction ( Cr &gt; 1.5mg/dL Cr clearance &lt; 60mL/m2 ) liver dysfunction ( AST/ALT &gt; 2x upper limit normal ( ULN ) ) Currently receive progestin therapy ( local , topical , systemic ) Myometrial invasion &gt; 50 % evidence nodal metastatic disease baseline MRI ( MRI do EC patient ) tumor size &gt; 2cm MRI pelvic ultrasound Mixed histology include clear cell , serous , undifferentiated sarcomatous element Prior current use metformin within past 3 month History hypersensitivity metformin history discontinuation secondary attribute adverse effect Chronic ( daily use &gt; 1 month ) use cimetidine ( significant increase metformin concentration risk lactic acidosis ) Iodinated contrast agent use prior 48 hour ( significant increase metformin concentration risk lactic acidosis ) Pregnant lactate Recent ( &lt; 4 week ) active , document , cervical infection</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2016</verification_date>
	<keyword>metformin</keyword>
	<keyword>endometrial cancer</keyword>
	<keyword>Lineberger Comprehensive Cancer Center</keyword>
	<keyword>complex atypical hyperplasia</keyword>
</DOC>